An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression

Journal of Clinical Psychiatry

Volumn 70, Issue 3, 2009, Pages 387-396

  Trivedi, Madhukar H ^a   Thase, Michael E ^b   Osuntokun, Olawale ^c   Henley, David B ^c   Case, Michael ^c   Watson, Susan B ^c   Campbell, Giedra M ^c   Corya, Sara A ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; NORTRIPTYLINE; OLANZAPINE; VENLAFAXINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CYCLOHEXANOL DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DISTURBANCE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSPEPSIA; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERSOMNIA; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SOMNOLENCE; SYMPTOM; TREMOR; WEIGHT CHANGE; WEIGHT GAIN; XEROSTOMIA; COMPARATIVE STUDY; DRUG COMBINATION; DRUG RESISTANCE; MAJOR DEPRESSION; MIDDLE AGED; PERSONALITY TEST; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; STATISTICS; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; NORTRIPTYLINE; PERSONALITY INVENTORY; PSYCHOMETRICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 64149130671     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04064     Document Type: Article

References (40)

1. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200 (Pubitemid 26184098)
2. Clinical Practice Guideline Number 5: Depression in Primary Care, 1: Detection and Diagnosis. Rockville, Md: Agency for Health Care Policy and Research, US Dept of Health and Human Services; 1993
3. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40 (Pubitemid 43050100)
4. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-1252
5. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-1242
6. Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry 2004;65:341-347
7. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 16):26-31 (Pubitemid 32685969)
8. Keller MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry 1998;44:348-360 (Pubitemid 28432646)
9. Maj M, Veltro F, Pirozzi R, et al. Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am J Psychiatry 1992;149:795-800
10. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997;58(suppl 13):23-29 (Pubitemid 28011969)
11. European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products. Note for guidance on clinical investigation of medicinal products in the treatment of depression. http://www.emea.europa.eu/ pdfs/human/ewp/051897en.pdf. April 25, 2002. Accessibility verified January 26, 2009
12. Ruhe HG, Huyser J, Swinkels JA, et al. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006;67(12):1836-1855 (Pubitemid 46055194)
13. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-1917 (Pubitemid 44807782)
14. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006;163:1161-1172 (Pubitemid 44464443)
15. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006;163:1519-1530 (Pubitemid 44465751)
16. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006;163:1531-1541 (Pubitemid 44465752)
17. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999;9:83-91 (Pubitemid 29073687)
18. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. Br J Psychiatry 1999;175:12-16 (Pubitemid 29307849)
19. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007;68(2):224-236 (Pubitemid 46362643)
20. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-134 (Pubitemid 32047260)
21. Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005;66(10):1289-1297 (Pubitemid 41546509)
22. Corya SA, Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006;23:364-372 (Pubitemid 44619788)
23. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389 (Pubitemid 9136500)
24. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;45(suppl 212):11-19
25. National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, Md: US National Institute of Health; 1976:534-537
26. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676 (Pubitemid 19154942)
27. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005;28(suppl 1):S37-S42 (Pubitemid 40095766)
28. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
29. Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry 2005;66(suppl 8):13-21 (Pubitemid 43004171)
30. Papakostas GI, Shelton RC, Smith J, et al. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 2007;68(6):826-831 (Pubitemid 47015480)
31. Joffe R, Sokolov S, Streiner D. Antidepressant treatment of depression: a metaanalysis. Can J Psychiatry 1996;41:613-616 (Pubitemid 27062617)
32. Kirsch I, Sapirstein G. Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prev Treat 1998;1(2). http://journals.apa.org/prevention/volume1/pre0010002a.html. Accessed Oct 16, 2006
33. Dube S, Tollefson GD, Thase ME, et al. Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord 2007;9:618-627 (Pubitemid 47365630)
34. Reeves H, Batra S, May RS, et al. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008;69(8):1228-1236
35. Montgomery SA, Bech P, Blier P, et al. Selecting methodologies for the evaluation of differences in time to response between antidepressants. J Clin Psychiatry 2002;63(8):694-699
36. Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007;164:1035-1043 (Pubitemid 47121392)
37. Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 2001;12:411-420 (Pubitemid 32324653)
38. International Conference on Harmonisation. Guidance for industry E14: clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Rockville, Md: US Food and Drug Administration; 2005
39. Patten SB. Recall bias and major depression lifetime prevalence. Soc Psychiatry Psychiatr Epidemiol 2003;38:290-296 (Pubitemid 37160797)
40. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 2006;75:139-153